Combined with the pharmacological effects of similar drugs, it is speculated that YXB components should be able to inhibit inflammation, NF-κB signaling pathway, and pain sensation in the treatment of LDH, RA, and AS. This evidence concerns the gene NFKB1 and rheumatoid arthritis.